Pharmaceutical From Standard to Specialist Capsule Formats Hard gelatin, HPMC, inhalation and vaginal formats engineered for every therapeutic need.
Nutraceutical Consumer-Ready Nutraceutical Formats Capsules and branded ingredients built for supplement manufacturers who demand differentiation.
Pharmaceutical CDMO
Accelerating Drug Development
Our Innovaform Accelerator and Tampa facility combine formulation science with scalable manufacturing.
CDMO Partnership
Full-Service Nutraceutical Manufacturing
From concept to market-ready product — your end-to-end nutraceutical development partner.
Applications
Our Story
Partners in Drug Delivery Innovation
A global leader in capsule technologies, committed to advancing pharmaceutical and nutraceutical science.
Capsules
Targeting the distal small intestine, specifically the terminal ileum, remains one of the greatest challenges in oral drug delivery.
Innovation in oral formulation technologies has opened new avenues for the lifecycle management and patent protection of biologics. Technologies such as SNAC, LBFs, HIPs, permeation enhancers, and Capsugel® Enprotect® capsules are now enabling the oral delivery of biologics. This step forward has the potential to benefit patients (with increased choice and accessibility), the healthcare system (with reduced staff workload and waste), and pharmaceutical companies (with extended patent protections).
The success and adoption of oral GLP-1 RAs mark a shift in biologic drug delivery. Technologies such as permeation enhancers, LBFs, and enteric protection have made the oral delivery of biologics a reality. By combining biologic level efficacy with the convenience and reach of oral dosing, formulators can open the door to more patient centric therapies, earlier intervention, and broader access, setting the foundation for a future in which oral biologics are no longer the exception, but the expectation.
Healthcare systems are facing increasing pressure as record demand, an aging population, the burden of chronic disease, and economic inflation challenge clinics, hospitals, and healthcare professionals to adequately keep up.1,2 Workforce supply shortages and tight healthcare budgets, especially since COVID-19, contribute to significant capacity issues across the healthcare system, e.g. poor access to appointments across primary and secondary care and discharge delays
Meeting consumers’ needs is the first priority for any successful business. For over-the-counter (OTC) medications and supplements, oral dosage forms have long been the cornerstone of self-administration. Traditionally, capsules have been composed of gelatin derived from cattle or pig bones and hides.1 Gelatin produces a high-gloss capsule that can be manufactured in many colors, offering attractive product packaging and easy swallowability—both positives for consumers. However, many consumers are now more concerned about the ethics of what they purchase and consume.2 In a recent survey, 70% of consumers said they believe it’s “important” or “very important” that the health and wellness products they buy are also eco-friendly and/or ethically produced, and 71% are willing to pay more for wellness products with these attributes.
The capsule market is shifting due to the growing importance of ethics and sustainability in driving consumer behavior. The ethical spending market has shown year-on-year growth since 1999, and spending on ethical products grew by over 20% in 2022 alone.
Maximizing Productivity in Vegan and Vegetarian Capsules Filling
Delivering orally bioavailable biologic modalities requires expertise in multiple fields. Lonza Capsugel scientists and technologists are dedicated to working with you to optimize every aspect of your formulation, from concept to commercialization, to deliver a viable oral dosage form.
Biological therapies have transformed the treatment of chronic and complex diseases, yet their impact is often limited by the need for parenteral administration. Oral delivery of biologics represents a major opportunity to improve patient experience, adherence, and healthcare efficiency, but achieving it has historically been constrained by poor stability and low bioavailability of the API in the gastrointestinal (GI) tract.
In our latest podcast, Lonza Capsugel’s Frank Romanski explores how patient preference is reshaping development strategies.
For years, oral delivery of biologics has been viewed as impractical. But what if the issue is not the route, but the approach?
Understanding patient attitudes and preferences has become an essential part of modern therapeutic decision making. The effectiveness of therapies doesn’t solely depend on the action of the medication itself, but also on additional factors, e.g. how it is formulated and administered.
Pre-clinical studies are essential for evaluating the safety, pharmacokinetics, and efficacy of drug candidates before entering human trials.
Poster presentation delivered at the Controlled Release Society (CRS) Annual Meeting, 2025.
At the Innovaform® Accelerator, we’re commited to advancing drug delivery through collaboration and cutting-edge science.
Explore how Lonza’s advanced polymer science and capsule manufacturing capabilities - Capsugel® Enprotect® - have led to a breakthrough in enteric protection.
Unlocking the full potential of many therapies hinges on effective absorption in the lower GI tract. Yet, delivering fragile APIs to the right location is no small feat.
The lower gastrointestinal tract is critical for enhancing bioavailability and drug absorption, directly influencing therapeutic efficacy.
Enteric capsules have many applications. Their principal purpose is to prevent the release of active pharmaceutical ingredients (APIs) in the stomach and to avoid them being exposed to gastric acid.
The lower GI tract plays an important role in how well drugs are absorbed and utilized by the body. But delivering sensitive APIs to this region—especially those vulnerable to acidic environments.
The lower gastro-intestinal tract plays an important role in optimizing bio-availability and drug absorption – and therefore the effectiveness of many therapies. But delivering sensitive APIs to the right location is a challenge. In a series of ‘real world’ questions, we explore the options and solutions when it comes to the targeted delivery of acid-sensitive APIs.
These findings confirm that Capsugel® Enprotect® capsules offer a robust, scalable, & patient-friendly alternative to traditional double-encapsulation methods
This downloadable summary features findings from a peer-reviewed study evaluating the in vivo performance of Capsugel® Enprotect® capsules
Delve contrasts between traditional coating methods with newer bi-layered polymer technologies, such as those used in Capsugel® Enprotect® capsules
Discover how Capsugel® Enprotect® capsule’s bi-layered polymer technology enables targeted enteric delivery—without the need for post-filling coating.
This Product Specification Brochure provides an overview of the Capsugel® Enprotect® capsule. It details the capsule’s composition, performance, data on dissolution, disintegration, size, color options, and stability.
Capsugel® Enprotect® is a ready-to-use enteric capsule with acid resistance up to pH 6.0, eliminating the need for post-filling coating. This scientific brochure presents evidence supporting the capsule’s performance.
Capsule-based Dry Powder Inhaler (cDPI) represents a prominent solution in the inhalation therapy domain. This poster explores the influence of capsule type on cDPI performance.
Faecal microbiota transplantation (FMT) is a highly effective treatment for diseases where the intestinal microbiota is compromised, particularly Clostridioides difficile infection.
Across two days our program will include eight specialized topic areas diving into specific developments within the industry, from formulation & delivery
In this study, the performance of Capsugel® Enprotect® capsules was evaluated using the DGM-intestinal model after intake in fasted and fed state and compared to in vivo data.
Respiratory Drug Delivery is a premier, international conference series providing comprehensive coverage of all aspects of drug delivery to the lungs and nose.
This study shows that Capsugel® Enprotect® capsules are stable and compatible with standard FMT placebo formulation
On January 15, 2025, the U.S. FDA announced that FD&C Red No. 3 (erythrosine, E127) colorant will no longer be authorized for use in foods and ingested drugs.
Aanchal Tomar Executive Director, Asia Pacific, Lonza CHI interview where she speaks about Lonza Capsules & Health Ingredients' strategic growth, challenges, and sustainability initiatives in the APAC market
Fecal Microbiota Transplant (FMT) oral delivery is a challenge. Today, fecal suspensions are concentrated, double-encapsulated in size 0 and 00 capsules and then stored at -80°C for 2 years.
Following a busy year for innovation in pharmaceutical manufacturing technologies – and many worthy nominees, we can now announce the grand winner of The Medicine Maker Innovation Awards.
Get more information about Capsugel® DBcaps® capsule with this FAQ.
Request a brochure or sample of Capsugel® Enprotect® Capsule - First of its kind enteric technology
The empty hard capsules are supplied as an excipient that is filled by pharmaceutical manufacturers with a variety of different formulations and products. To understand the potential variations of the empty hard capsules as an input parameter and its potential impact on the finished product quality, a study was performed investigating the critical quality parameters within and in between different batches of empty hard gelatin capsules. Hard capsules can be considered as a suitable excipient for product development using QbD principles.
This paper provides a technical review of formulation considerations relating to the use of gelatin Capsugel® DBcaps® capsules for clinical trials, as well as a list of published references.